

What is claimed is:

1. A method for inhibiting the growth or proliferation of a colon neoplasia in a subject, the method comprising administering to the subject an agent that
5 decreases the amount of a polypeptide present in or produced by the colon neoplasia, said polypeptide selected from among: ColoUp1, ColoUp2, ColoUp3, ColoUp4, ColoUp5, ColoUp6, ColoUp7 and ColoUp8.
2. The method of claim 1, wherein the agent is an siRNA probe that hybridizes to an mRNA encoding a polypeptide selected from among: ColoUp1, ColoUp2,
10 ColoUp3, ColoUp4, ColoUp5, ColoUp6, ColoUp7 and ColoUp8.
3. The method of claim 2, wherein the siRNA probe hybridizes to a nucleic acid selected from among: SEQ ID Nos. 4, 5 and 7-12.
4. The method of claim 1, wherein the agent is an antisense probe that hybridizes to a nucleic acid encoding a polypeptide selected from among: ColoUp1, ColoUp2,
15 ColoUp3, ColoUp4, ColoUp5, ColoUp6, ColoUp7 and ColoUp8.
5. The method of claim 4, wherein the antisense probe hybridizes to a nucleic acid selected from among: SEQ ID Nos. 4, 5 and 7-12.
6. The method of claim 1, wherein the agent is a nucleic acid vector that causes the production of a siRNA or an antisense probe that hybridizes to a nucleic acid
20 encoding a polypeptide selected from among: ColoUp1, ColoUp2, ColoUp3, ColoUp4, ColoUp5, ColoUp6, ColoUp7 and ColoUp8.
7. The method of claim 6, wherein the siRNA or antisense probe hybridizes to a nucleic acid selected from among: SEQ ID Nos. 4, 5 and 7-12.
8. A method for inhibiting the growth or proliferation of a cell of a colon neoplasia
25 in a subject, the method comprising administering to the subject an agent that binds to and antagonizes a polypeptide selected from among: ColoUp1, ColoUp2, ColoUp3, ColoUp4, ColoUp5, ColoUp6, ColoUp7 and ColoUp8.
9. The method of claim 8, wherein the agent is an antibody that binds to a polypeptide selected from among ColoUp1, ColoUp2, ColoUp3, ColoUp4,
30 ColoUp5, ColoUp6, ColoUp7 and ColoUp8.

10. The method of claim 9, wherein the polypeptide is selected from among: SEQ ID Nos. 1-3, 13, 14 and 16-21.
11. The method of claim 9, wherein the antibody comprises a monoclonal antibody.
12. The method of claim 9, wherein the antibody comprises a polyclonal antibody.
- 5 13. The method of claim 9, wherein the antibody comprises a single chain antibody.
14. The method of claim 9, wherein the antibody comprises a humanized antibody.
15. The method of claim 8, wherein the agent is a small molecule that binds to a polypeptide selected from among: SEQ ID Nos. 1-3, 13, 14 and 16-21.
- 10 16. A therapeutic agent that is targeted to a colon neoplasia, the agent comprising a targeting moiety and an active moiety, wherein the targeting moiety binds to a polypeptide selected from among ColoUp1, ColoUp2, ColoUp3, ColoUp4, ColoUp5, ColoUp6, ColoUp7 and ColoUp8 and wherein the active moiety facilitates the killing or growth inhibition of a cell of a colon neoplasia.
- 15 17. The therapeutic agent of claim 16, wherein the targeting moiety comprises an antibody.
18. The therapeutic agent of claim 17, wherein the antibody binds to a polypeptide selected from among SEQ ID Nos. 1-3, 13, 14 and 16-21.
19. The therapeutic agent of claim 18, wherein the antibody is selected from among: a monoclonal antibody, a polyclonal antibody, a single chain antibody.
- 20 20. The therapeutic agent of claim 18, wherein the antibody is a humanized antibody.
21. The therapeutic agent of claim 16, wherein the active moiety sensitizes the cell to a chemotherapeutic agent or radiation.
22. A method of identifying a candidate agent for treating colon cancer, the method comprising: identifying a candidate agent that binds to and/or inhibits an activity of a polypeptide selected from among: ColoUp1, ColoUp2, ColoUp3, ColoUp4, ColoUp5, ColoUp6, ColoUp7 and ColoUp8.
- 25 23. The method of claim 22, further comprising testing the candidate agent for antineoplastic effects on a cell of a colon neoplasia or a cell of a cell line derived from a colon neoplasia.

24. The method of claim 22, further comprising testing the candidate agent for antineoplastic effects on a mouse xenograft comprising cells of a human colon cancer or cells of a cell line derived from a colon cancer cell line.
25. The method of claim 22, wherein the candidate agent is a siRNA probe or an antisense probe.
26. The method of claim 22, wherein the candidate agent is an antibody.
27. The method of claim 22, wherein the candidate agent is a small molecule.

5